These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 29379963)

  • 1. Circadian Rest-Activity Pattern Changes in Aging and Preclinical Alzheimer Disease.
    Musiek ES; Bhimasani M; Zangrilli MA; Morris JC; Holtzman DM; Ju YS
    JAMA Neurol; 2018 May; 75(5):582-590. PubMed ID: 29379963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
    Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
    JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology.
    Gordon BA; Blazey T; Su Y; Fagan AM; Holtzman DM; Morris JC; Benzinger TL
    JAMA Neurol; 2016 Oct; 73(10):1192-1200. PubMed ID: 27548756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels.
    Babulal GM; Ghoshal N; Head D; Vernon EK; Holtzman DM; Benzinger TLS; Fagan AM; Morris JC; Roe CM
    Am J Geriatr Psychiatry; 2016 Nov; 24(11):1095-1104. PubMed ID: 27426238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease.
    Villeneuve S; Vogel JW; Gonneaud J; Pichet Binette A; Rosa-Neto P; Gauthier S; Bateman RJ; Fagan AM; Morris JC; Benzinger TLS; Johnson SC; Breitner JCS; Poirier J;
    JAMA Neurol; 2018 May; 75(5):608-619. PubMed ID: 29482212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.
    Tarawneh R; D'Angelo G; Crimmins D; Herries E; Griest T; Fagan AM; Zipfel GJ; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2016 May; 73(5):561-71. PubMed ID: 27018940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Preclinical Alzheimer Disease With Optical Coherence Tomographic Angiography Findings.
    O'Bryhim BE; Apte RS; Kung N; Coble D; Van Stavern GP
    JAMA Ophthalmol; 2018 Nov; 136(11):1242-1248. PubMed ID: 30352114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer's disease.
    Twohig D; Rodriguez-Vieitez E; Sando SB; Berge G; Lauridsen C; Møller I; Grøntvedt GR; Bråthen G; Patra K; Bu G; Benzinger TLS; Karch CM; Fagan A; Morris JC; Bateman RJ; Nordberg A; White LR; Nielsen HM;
    Acta Neuropathol Commun; 2018 Nov; 6(1):130. PubMed ID: 30477568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sleep quality and preclinical Alzheimer disease.
    Ju YE; McLeland JS; Toedebusch CD; Xiong C; Fagan AM; Duntley SP; Morris JC; Holtzman DM
    JAMA Neurol; 2013 May; 70(5):587-93. PubMed ID: 23479184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exercise and Alzheimer's disease biomarkers in cognitively normal older adults.
    Liang KY; Mintun MA; Fagan AM; Goate AM; Bugg JM; Holtzman DM; Morris JC; Head D
    Ann Neurol; 2010 Sep; 68(3):311-8. PubMed ID: 20818789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 11C-PiB imaging of human immunodeficiency virus-associated neurocognitive disorder.
    Ances BM; Benzinger TL; Christensen JJ; Thomas J; Venkat R; Teshome M; Aldea P; Fagan AM; Holtzman DM; Morris JC; Clifford DB
    Arch Neurol; 2012 Jan; 69(1):72-7. PubMed ID: 22232345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease.
    Vlassenko AG; McCue L; Jasielec MS; Su Y; Gordon BA; Xiong C; Holtzman DM; Benzinger TL; Morris JC; Fagan AM
    Ann Neurol; 2016 Sep; 80(3):379-87. PubMed ID: 27398953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circadian disturbances in Alzheimer's disease progression: a prospective observational cohort study of community-based older adults.
    Li P; Gao L; Gaba A; Yu L; Cui L; Fan W; Lim ASP; Bennett DA; Buchman AS; Hu K
    Lancet Healthy Longev; 2020 Dec; 1(3):e96-e105. PubMed ID: 34179863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.
    Wang L; Benzinger TL; Su Y; Christensen J; Friedrichsen K; Aldea P; McConathy J; Cairns NJ; Fagan AM; Morris JC; Ances BM
    JAMA Neurol; 2016 Sep; 73(9):1070-7. PubMed ID: 27454922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
    Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.
    Morris JC; Roe CM; Xiong C; Fagan AM; Goate AM; Holtzman DM; Mintun MA
    Ann Neurol; 2010 Jan; 67(1):122-31. PubMed ID: 20186853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The circadian rest-activity pattern predicts cognitive decline among mild-moderate Alzheimer's disease patients.
    Targa ADS; Benítez ID; Dakterzada F; Fontenele-Araujo J; Minguez O; Zetterberg H; Blennow K; Barbé F; Piñol-Ripoll G
    Alzheimers Res Ther; 2021 Sep; 13(1):161. PubMed ID: 34563258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
    Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
    Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
    Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
    J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.